281 related articles for article (PubMed ID: 24091715)
1. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
Vejpongsa P; Yeh ET
Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
6. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
10. Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
Zhang S; Liu X; Bawa-Khalfe T; Lu LS; Lyu YL; Liu LF; Yeh ET
Nat Med; 2012 Nov; 18(11):1639-42. PubMed ID: 23104132
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
13. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.
Henninger C; Fritz G
Cell Death Dis; 2017 Jan; 8(1):e2564. PubMed ID: 28102848
[TBL] [Abstract][Full Text] [Related]
14. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
15. Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.
Menna P; Salvatorelli E
Chemotherapy; 2017; 62(3):159-168. PubMed ID: 28122377
[TBL] [Abstract][Full Text] [Related]
16. The flavonoid quercetin: possible solution for anthracycline-induced cardiotoxicity and multidrug resistance.
Czepas J; Gwoździński K
Biomed Pharmacother; 2014 Oct; 68(8):1149-59. PubMed ID: 25458790
[TBL] [Abstract][Full Text] [Related]
17. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
18. [Ranolazine in the prevention of anthracycline-related cardiotoxicity].
Corradi F; Paolini L; De Caterina R
G Ital Cardiol (Rome); 2013 Jun; 14(6):424-37. PubMed ID: 23748539
[TBL] [Abstract][Full Text] [Related]
19. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
20. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
